Today announced the completion of scale-up production of ANAVEX 2-73.

Anavex completes manufacturing of Alzheimer’s disease drug ANAVEX 2-73 for its clinical trials Anavex Lifestyle Sciences Corp xenical 120mg ., today announced the completion of scale-up production of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ‘With enough levels of ANAVEX 2-73 in hand we are an important step nearer to the commencement of Phase I scientific trials, which are scheduled to begin in early 2010,’ said Dr. Herve de Kergrohen, CEO of ANAVEX. ‘This lead drug candidate shows potential to improve the course of Alzheimer’s disease through the use of sigma receptors to correct dysfunction in the mitochondria and ultimately secure cells from oxidative stress, which is believed to be an underlying cause of the disease.’ Related StoriesIU-led researchers discover fresh gene that increases Alzheimer's disease riskExperimental drug candidate aimed at combating Alzheimer's disease offers anti-aging effectsSalsalate drug presents new expect treating Alzheimer's disease and FTDANAVEX can shortly announce selecting the Contract Research Organization responsible for carrying out its Stage I clinical trials.

Justice Division investigation into whether Republican presidential contender Newt Gingrich worked as an unregistered lobbyist. The brand new complaint targets a 2003 debate over the expansion of Medicare, the federal government health program for older people. Gingrich tried to influence the debate while he was mind of a coalition of health care businesses that stood to benefit financially from potential changes, the complaint says . Politico Pro: CREW REQUESTS Probe Of Gingrich Wellness Group A authorities watchdog group, Residents for Responsibility and Ethics in Washington, offers asked the FBI and the Justice Division to investigate whether Newt Gingrich violated lobbying laws by failing to register as a healthcare lobbyist and by not filing lobbying disclosure reviews.